ArrayPatch raises €3.2 million for GLP-1 microneedle skin patch

ArrayPatch, a biotech start-up spun out of University College Cork (UCC) in Ireland, said on Thursday, 5 November 2026 that it has completed an oversubscribed seed funding round of €3.2 million. The company is developing skin patches covered in tiny, dissolving needles made of the medicine itself, and its lead programme aims to deliver GLP-1 drugs, the class of medicines used for obesity and type 2 diabetes, through a patch instead of an injection. A second close added €1.6 million to the €1.6 million raised in the first close earlier this year.

A microneedle patch is a small sticker whose underside carries hundreds of very short needles. They pierce only the outer layer of the skin and, in ArrayPatch's design, release a drug as they dissolve. The company says its needles are polymer-free, meaning they have no plastic-like carrier material, and are made of the medicine itself. These are the company's claims; the patches have not yet been tested in people.

The GLP-1 focus is the headline. GLP-1 medicines are used for weight loss and type 2 diabetes, and ArrayPatch's aim is to replace an injection with a patch, which would be simpler for patients if it worked as well. Whether ArrayPatch's approach can deliver enough of these large, complex molecules through the skin is exactly what its upcoming studies will need to show.

The company's other two programmes target the skin directly. Basal cell carcinoma grows in the skin, and nail fungus sits under the nail, so a patch that delivers medicine at the spot could, if proven, reduce the need for surgery or long courses of tablets. Again, these are aims, not results.

For founders and investors, the round is a typical example of a university spin-out path: lab research at UCC, a company formed in 2024, a seed round led by a private investor with the state agency Enterprise Ireland and angel syndicates joining, and the money tied to reaching first studies in people. For Indian founders and university incubators building health-tech, it shows how a seed round can be tied to one clear milestone: the first study in people.

Peepals calculation: ArrayPatch set out to raise €3 million and ended with €3.2 million, about €0.2 million or roughly 6.7% more than its target (0.2 ÷ 3 ≈ 0.067). The two closes were equal: €1.6 million each (1.6 + 1.6 = 3.2), so the second close doubled the money raised at the first. Our calculation from the reported figures.

Short-term: ArrayPatch has the money to carry its patch programmes towards first-in-human studies, starting with the GLP-1 obesity and diabetes patch and the basal cell carcinoma patch.

Long-term: If the patches prove safe and effective in human trials, which will take years and is not certain, they could offer a needle-free way to take some drugs that are now injected. If they do not, the round will have funded the test of an idea that many drug-delivery companies are chasing.

Who is affected: People living with obesity, type 2 diabetes, basal cell carcinoma or nail fungus who may one day benefit if the products succeed; drug-delivery researchers; university spin-outs and early-stage health-tech investors.

Questions and Answers